Related references
Note: Only part of the references are listed.Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma
Robert M. Rifkin et al.
PHARMACOECONOMICS-OPEN (2020)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Quality of life in multiple myeloma: considerations and recommendations
Samantha Seitzler et al.
EXPERT REVIEW OF HEMATOLOGY (2019)
Patient-Reported Factors in Treatment Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Ajai Chari et al.
ONCOLOGIST (2019)
High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action
Homer C. Adams et al.
CYTOMETRY PART A (2019)
Valuing health-related quality of life: An EQ-5D-5L value set for England
Nancy J. Devlin et al.
HEALTH ECONOMICS (2018)
Age-Related Patterns in Cancer Pain and Its Psychosocial Impact: Investigating the Role of Variability in Physical and Mental Health Quality of Life
Lynn R. Gauthier et al.
PAIN MEDICINE (2018)
NCCN Guidelines (R) Insights Multiple Myeloma, Version 3.2018 Featured Updates to the NCCN Guidelines
Shaji K. Kumar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Health-related quality of life in patients with newly diagnosed multiple myeloma who are ineligible for stem cell transplantation: Results from the ALCYONE trial.
Katharine Gries et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. Moreau et al.
ANNALS OF ONCOLOGY (2017)
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik et al.
BLOOD (2016)
The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study
Christina Ramsenthaler et al.
BMC CANCER (2016)
Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis
Christina Ramsenthaler et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
Niels W. C. J. van de Donk et al.
IMMUNOLOGICAL REVIEWS (2016)
The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking
Marije B. Overdijk et al.
JOURNAL OF IMMUNOLOGY (2016)
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Meletios A. Dimopoulos et al.
HAEMATOLOGICA (2015)
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
Marije B. Overdijk et al.
MABS (2015)
Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life
R. Baz et al.
SUPPORTIVE CARE IN CANCER (2015)
Palliative Care in Older Patients With Cancer
Lodovico Balducci et al.
CANCER CONTROL (2015)
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Meletios A. Dimopoulos et al.
HAEMATOLOGICA (2015)
Relationship between Onset of Pain Relief and Patient Satisfaction with Fentanyl Pectin Nasal Spray for Breakthrough Pain in Cancer
Luis M. Torres et al.
JOURNAL OF PALLIATIVE MEDICINE (2014)
Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial
Meletios A. Dimopoulos et al.
LEUKEMIA & LYMPHOMA (2014)
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Lotfi Benboubker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial
Michel Delforge et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma
Ann Kristin Kvam et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
Michel de Weers et al.
JOURNAL OF IMMUNOLOGY (2011)
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
M. Herdman et al.
QUALITY OF LIFE RESEARCH (2011)
Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
Maria-Victoria Mateos et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer
A. Simon Pickard et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2007)
Share Paper
